Many companies have failed to discover inhibitors of this important component of the immune activation system. We have already generated attractive hit compounds that are undergoing further analysis and testing.
Many companies are developing PIM inhibitors. To date most are not specific and inhibit many PIM isoforms. We believe that a specific PIM 3 inhibitor will have superior efficacy and safety compared to non-specific inhibitors.
cGAS/STINGAutoimmune Disease and Cancer
The cGAS STING pathway allows cells to detect cytosolic DNA fragments that trigger a robust immune response against pathogens and cancer cells. Early STING agonists have failed to perform well in clinical trials, however, the discovery of compelling antagonists to the STING pathway could provide treatments for systemic lupus erythematosus (SLE) and other autoimmune conditions.
Factor XIIa is a component of the clotting cascade. Inactivating mutations of this factor (Hageman Factor) results in the prevention of thrombosis without promoting the pathological bleeding associated with current treatments. A small-molecule inhibitor would be a safer alternative to current anticoagulants, such as heparin, warfarin, and factor 10 inhibitors, for the prevention of clots in susceptible patients. In silico screening is currently in progress.
SHP2 is a critical driver of certain cancers. SHP2 is an enzyme type that has been more difficult to target compared to kinases. We have already generated attractive hit compounds that are undergoing further analysis and testing.